

## **SUPPLEMENTARY TABLE**

**Predicting chemotherapy-induced thrombocytopenia in cancer patients with solid tumors  
or lymphoma**

**Supplementary Table** Thrombocytopenia risk groups of the chemotherapy regimens

Regimen	Thrombocytopenia Risk Group
<b>Breast cancer</b>	
DD AC followed by paclitaxel [1]	Low
TAC [2]	Low
TH [3]	Low
DD EC [4]	High
AC every 21 days [1]	Low
FEC followed by docetaxel [5]	Low
TC [6]	Low
Docetaxel every 21 days [7]	Low
EC every 21 days [8]	Low
TCH [3]	Intermediate
Docetaxel/ gemcitabine [9]	Low
Gemcitabine/ vinorelbine [10]	Low
Capecitabine + trastuzumab [11]	Low
<b>Colorectal cancer</b>	
FOLFOX4 [12]	Low
FOLFIRI [12]	Low
modified-FOLFOX6 [13, 14]	Low
FOLFIRINOX + cetuximab [15]	Intermediate
Oxaliplatin/ capecitabine [16, 17]	Low
<b>Esophageal &amp; gastric cancers</b>	
TPF [18]	Low
LVFU [19]	Low
ECX [20]	Low
EOX [21]	Low
PCF [22, 23]	Intermediate
DOF [24]	Low
Cisplatin/ 5FU + RT [25]	Low
Paclitaxel/ carboplatin + RT [26]	Low
<b>Bladder cancer</b>	
Gemcitabine/ cisplatin [27]	High
Gemcitabine/ carboplatin [28]	High

Testicular cancer	
BEP [29]	Intermediate
EP [30, 31]	Low
Carboplatin [32]	Low
Sarcomas	
Ifosfamide / doxorubicin [33]	High
VAC [34]	High
EVAIA [35]	High
Ifosfamide/ etoposide [36]	High
Ifosfamide/ mesna [37]	Low
Head & neck cancers	
TPF [38]	Low
Cisplatin + RT [39]	Low
Prostate cancer	
Docetaxel/ prednisone [40]	Low
Lymphomas	
R-CHOP-21 [41]	Intermediate
ABVD [42]	Low
R-GCVP [43]	High
Lung cancer	
EP [44, 45]	Intermediate
Cisplatin/ vinorelbine [46]	Low
Cisplatin/ paclitaxel [47]	Low
Carboplatin/ paclitaxel [47]	Intermediate
Ovarian cancer	
BEP [29]	Intermediate
Paclitaxel/ carboplatin [48]	Low
Endometrial & cervical cancers	
Paclitaxel/ cisplatin [49]	Low
Paclitaxel/ carboplatin [50]	Intermediate
Cisplatin + RT [51, 52]	Low
Pancreatic cancer	
Gemcitabine/ cisplatin [53]	High

Brain cancer	
Cisplatin/ lomustine/ vincristine [54]	High
Anal cancer	
5FU/ mitomycin + RT [55, 56]	Low
Melanoma	
Paclitaxel/ carboplatin [57]	Low
Occult primary cancer	
Paclitaxel/ carboplatin [58]	Low

---

ABVD, doxorubicin/ bleomycin/ vinblastine/ dacarbazine; AC, doxorubicin/ cyclophosphamide; BEP, bleomycin/ etoposide/ cisplatin; DD, dose-dense; DOF, docetaxel/ oxaliplatin/ 5-fluorouracil; ECX, epirubicin/ cisplatin/ capecitabine; EC, epirubicin/ cyclophosphamide; EOX, epirubicin/ oxaliplatin/ capecitabine; EP, etoposide/ cisplatin; ; EVAIA, etoposide/ vincristine/ actinomycin-D/ ifosfamide/ doxorubicin; FEC, fluorouracil/ epirubicin/ cyclophosphamide; FOLFIRI, 5-FU/ I-folinic acid/ d,l-folinic acid/ irinotecan; FOLFIRINOX, 5-FU/ folinic acid/ oxaliplatin/ irinotecan; FOLFOX, 5-FU/ folinic acid/ oxaliplatin; LVFU, leucovorin-primed fluorouracil; PCF, paclitaxel/ cisplatin/ 5-fluorouracil; RT, radiotherapy; R-CHOP, rituximab/ cyclophosphamide/ doxorubicin/ vincristine/ prednisone; R-GCVP, rituximab/ gemcitabine/ cyclophosphamide/ vincristine/ prednisolone; TAC, docetaxel/ doxorubicin/ cyclophosphamide; TC, docetaxel/ cyclophosphamide; TCH, docetaxel/ carboplatin/ trastuzumab; TH, docetaxel/ trastuzumab; TPF, docetaxel/ cisplatin/ 5-fluorouracil; VAC, vincristine/ actinomycin-D/ cyclophosphamide; 5FU, 5-fluorouracil.

## Supplementary References:

1. Citron ML, Berry DA, Cirincione C et al. Randomized trial of dose-dense versus conventionally scheduled and sequential versus concurrent combination chemotherapy as postoperative adjuvant treatment of node-positive primary breast cancer: first report of Intergroup Trial C9741/Cancer and Leukemia Group B Trial 9741. *Journal of clinical oncology : official journal of the American Society of Clinical Oncology* 2003; 21: 1431-1439.
2. Eiermann W, Pienkowski T, Crown J et al. Phase III study of doxorubicin/cyclophosphamide with concomitant versus sequential docetaxel as adjuvant treatment in patients with human epidermal growth factor receptor 2-normal, node-positive breast cancer: BCIRG-005 trial. *Journal of clinical oncology : official journal of the American Society of Clinical Oncology* 2011; 29: 3877-3884.
3. Valero V, Forbes J, Pegram MD et al. Multicenter phase III randomized trial comparing docetaxel and trastuzumab with docetaxel, carboplatin, and trastuzumab as first-line chemotherapy for patients with HER2-gene-amplified metastatic breast cancer (BCIRG 007 study): two highly active therapeutic regimens. *Journal of clinical oncology : official journal of the American Society of Clinical Oncology* 2011; 29: 149-156.

4. Therasse P, Mauriac L, Welnicka-Jaskiewicz M et al. Final results of a randomized phase III trial comparing cyclophosphamide, epirubicin, and fluorouracil with a dose-intensified epirubicin and cyclophosphamide + filgrastim as neoadjuvant treatment in locally advanced breast cancer: an EORTC-NCIC-SAKK multicenter study. *Journal of clinical oncology : official journal of the American Society of Clinical Oncology* 2003; 21: 843-850.
5. Roche H, Fumoleau P, Spielmann M et al. Sequential adjuvant epirubicin-based and docetaxel chemotherapy for node-positive breast cancer patients: the FNCLCC PACS 01 Trial. *Journal of clinical oncology : official journal of the American Society of Clinical Oncology* 2006; 24: 5664-5671.
6. Jones SE, Savin MA, Holmes FA et al. Phase III trial comparing doxorubicin plus cyclophosphamide with docetaxel plus cyclophosphamide as adjuvant therapy for operable breast cancer. *Journal of clinical oncology : official journal of the American Society of Clinical Oncology* 2006; 24: 5381-5387.
7. Jones SE, Erban J, Overmoyer B et al. Randomized phase III study of docetaxel compared with paclitaxel in metastatic breast cancer. *Journal of clinical oncology : official journal of the American Society of Clinical Oncology* 2005; 23: 5542-5551.
8. Moebus V, Jackisch C, Lueck HJ et al. Intense dose-dense sequential chemotherapy with epirubicin, paclitaxel, and cyclophosphamide compared with conventionally scheduled chemotherapy in high-risk primary breast cancer: mature results of an AGO phase III study. *Journal of clinical oncology : official journal of the American Society of Clinical Oncology* 2010; 28: 2874-2880.
9. Fountzilas G, Nicolaides C, Bafaloukos D et al. Docetaxel and gemcitabine in anthracycline-resistant advanced breast cancer: a Hellenic Cooperative Oncology Group Phase II study. *Cancer Invest* 2000; 18: 503-509.
10. Martin M, Ruiz A, Munoz M et al. Gemcitabine plus vinorelbine versus vinorelbine monotherapy in patients with metastatic breast cancer previously treated with anthracyclines and taxanes: final results of the phase III Spanish Breast Cancer Research Group (GEICAM) trial. *The Lancet. Oncology* 2007; 8: 219-225.
11. Bartsch R, Wenzel C, Altorjai G et al. Capecitabine and trastuzumab in heavily pretreated metastatic breast cancer. *Journal of clinical oncology : official journal of the American Society of Clinical Oncology* 2007; 25: 3853-3858.
12. Colucci G, Gebbia V, Paoletti G et al. Phase III randomized trial of FOLFIRI versus FOLFOX4 in the treatment of advanced colorectal cancer: a multicenter study of the Gruppo Oncologico Dell'Italia Meridionale. *Journal of clinical oncology : official journal of the American Society of Clinical Oncology* 2005; 23: 4866-4875.
13. Allegra CJ, Yothers G, O'Connell MJ et al. Initial safety report of NSABP C-08: A randomized phase III study of modified FOLFOX6 with or without bevacizumab for the adjuvant treatment of patients with stage II or III colon cancer. *Journal of clinical oncology : official journal of the American Society of Clinical Oncology* 2009; 27: 3385-3390.
14. Jeon H-J, Woo J-H, Lee H-Y et al. Adjuvant chemotherapy using the FOLFOX regimen in colon cancer. *Journal of the Korean Society of Coloproctology* 2011; 27: 140-146.

15. Assenat E, Desseigne F, Thezenas S et al. Cetuximab plus FOLFIRINOX (ERBIRINOX) as first-line treatment for unresectable metastatic colorectal cancer: a phase II trial. *Oncologist* 2011; 16: 1557-1564.
16. Cassidy J, Clarke S, Diaz-Rubio E et al. Randomized phase III study of capecitabine plus oxaliplatin compared with fluorouracil/folinic acid plus oxaliplatin as first-line therapy for metastatic colorectal cancer. *Journal of clinical oncology : official journal of the American Society of Clinical Oncology* 2008; 26: 2006-2012.
17. Feliu J, Salud A, Escudero P et al. XELOX (capecitabine plus oxaliplatin) as first-line treatment for elderly patients over 70 years of age with advanced colorectal cancer. *British journal of cancer* 2006; 94: 969-975.
18. Van Cutsem E, Moiseyenko VM, Tjulandin S et al. Phase III study of docetaxel and cisplatin plus fluorouracil compared with cisplatin and fluorouracil as first-line therapy for advanced gastric cancer: a report of the V325 Study Group. *Journal of clinical oncology* 2006; 24: 4991-4997.
19. Bouche O, Raoul JL, Bonnetain F et al. Randomized multicenter phase II trial of a biweekly regimen of fluorouracil and leucovorin (LV5FU2), LV5FU2 plus cisplatin, or LV5FU2 plus irinotecan in patients with previously untreated metastatic gastric cancer: a Federation Francophone de Cancerologie Digestive Group Study--FFCD 9803. *Journal of clinical oncology : official journal of the American Society of Clinical Oncology* 2004; 22: 4319-4328.
20. Rao S, Starling N, Cunningham D et al. Matuzumab plus epirubicin, cisplatin and capecitabine (ECX) compared with epirubicin, cisplatin and capecitabine alone as first-line treatment in patients with advanced oesophago-gastric cancer: a randomised, multicentre open-label phase II study. *Annals of oncology : official journal of the European Society for Medical Oncology* 2010; 21: 2213-2219.
21. Waddell T, Chau I, Cunningham D et al. Epirubicin, oxaliplatin, and capecitabine with or without panitumumab for patients with previously untreated advanced oesophagogastric cancer (REAL3): a randomised, open-label phase 3 trial. *The Lancet. Oncology* 2013; 14: 481-489.
22. Ilson DH, Ajani J, Bhalla K et al. Phase II trial of paclitaxel, fluorouracil, and cisplatin in patients with advanced carcinoma of the esophagus. *Journal of clinical oncology : official journal of the American Society of Clinical Oncology* 1998; 16: 1826-1834.
23. Kim YH, Shin SW, Kim BS et al. Paclitaxel, 5-fluorouracil, and cisplatin combination chemotherapy for the treatment of advanced gastric carcinoma. *Cancer* 1999; 85: 295-301.
24. Van Cutsem E, Boni C, Tabernero J et al. Docetaxel plus oxaliplatin with or without fluorouracil or capecitabine in metastatic or locally recurrent gastric cancer: a randomized phase II study. *Annals of oncology : official journal of the European Society for Medical Oncology* 2015; 26: 149-156.

25. Conroy T, Galais MP, Raoul JL et al. Definitive chemoradiotherapy with FOLFOX versus fluorouracil and cisplatin in patients with oesophageal cancer (PRODIGE5/ACCORD17): final results of a randomised, phase 2/3 trial. *The Lancet. Oncology* 2014; 15: 305-314.
26. van Hagen P, Hulshof MC, van Lanschot JJ et al. Preoperative chemoradiotherapy for esophageal or junctional cancer. *The New England journal of medicine* 2012; 366: 2074-2084.
27. von der Maase H, Hansen SW, Roberts JT et al. Gemcitabine and cisplatin versus methotrexate, vinblastine, doxorubicin, and cisplatin in advanced or metastatic bladder cancer: results of a large, randomized, multinational, multicenter, phase III study. *Journal of clinical oncology : official journal of the American Society of Clinical Oncology* 2000; 18: 3068-3077.
28. Shannon C, Crombie C, Brooks A et al. Carboplatin and gemcitabine in metastatic transitional cell carcinoma of the urothelium: effective treatment of patients with poor prognostic features. *Annals of oncology : official journal of the European Society for Medical Oncology* 2001; 12: 947-952.
29. Culine S, Kramar A, Theodore C et al. Randomized trial comparing bleomycin/etoposide/cisplatin with alternating cisplatin/cyclophosphamide/doxorubicin and vinblastine/bleomycin regimens of chemotherapy for patients with intermediate- and poor-risk metastatic nonseminomatous germ cell tumors: Genito-Urinary Group of the French Federation of Cancer Centers Trial T93MP. *Journal of clinical oncology : official journal of the American Society of Clinical Oncology* 2008; 26: 421-427.
30. Tjulandin SA, Garin AM, Mescheryakov AA et al. Cisplatin-etoposide and carboplatin-etoposide induction chemotherapy for good-risk patients with germ cell tumors. *Annals of oncology : official journal of the European Society for Medical Oncology* 1993; 4: 663-667.
31. Horwich A, Oliver RT, Wilkinson PM et al. A medical research council randomized trial of single agent carboplatin versus etoposide and cisplatin for advanced metastatic seminoma. MRC Testicular Tumour Working Party. *British journal of cancer* 2000; 83: 1623-1629.
32. Steiner H, Scheiber K, Berger AP et al. Retrospective multicentre study of carboplatin monotherapy for clinical stage I seminoma. *BJU Int* 2011; 107: 1074-1079.
33. Judson I, Verweij J, Gelderblom H et al. Doxorubicin alone versus intensified doxorubicin plus ifosfamide for first-line treatment of advanced or metastatic soft-tissue sarcoma: a randomised controlled phase 3 trial. *The Lancet. Oncology* 2014; 15: 415-423.
34. Arndt CA, Stoner JA, Hawkins DS et al. Vincristine, actinomycin, and cyclophosphamide compared with vincristine, actinomycin, and cyclophosphamide alternating with vincristine, topotecan, and cyclophosphamide for intermediate-risk rhabdomyosarcoma: children's oncology group study D9803. *Journal of clinical oncology : official journal of the American Society of Clinical Oncology* 2009; 27: 5182-5188.

35. Paulussen M, Craft AW, Lewis I et al. Results of the EICESS-92 Study: two randomized trials of Ewing's sarcoma treatment--cyclophosphamide compared with ifosfamide in standard-risk patients and assessment of benefit of etoposide added to standard treatment in high-risk patients. *Journal of clinical oncology : official journal of the American Society of Clinical Oncology* 2008; 26: 4385-4393.
36. Goorin AM, Harris MB, Bernstein M et al. Phase II/III trial of etoposide and high-dose ifosfamide in newly diagnosed metastatic osteosarcoma: a pediatric oncology group trial. *Journal of clinical oncology : official journal of the American Society of Clinical Oncology* 2002; 20: 426-433.
37. van Oosterom AT, Mouridsen HT, Nielsen OS et al. Results of randomised studies of the EORTC Soft Tissue and Bone Sarcoma Group (STBSG) with two different ifosfamide regimens in first- and second-line chemotherapy in advanced soft tissue sarcoma patients. *European journal of cancer (Oxford, England : 1990)* 2002; 38: 2397-2406.
38. Posner MR, Hershock DM, Blajman CR et al. Cisplatin and fluorouracil alone or with docetaxel in head and neck cancer. *The New England journal of medicine* 2007; 357: 1705-1715.
39. Hitt R, Grau JJ, López-Pousa A et al. A randomized phase III trial comparing induction chemotherapy followed by chemoradiotherapy versus chemoradiotherapy alone as treatment of unresectable head and neck cancer. *Annals of Oncology* 2014; 25: 216-225.
40. Tannock IF, de Wit R, Berry WR et al. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. *The New England journal of medicine* 2004; 351: 1502-1512.
41. Pfreundschuh M, Trumper L, Osterborg A et al. CHOP-like chemotherapy plus rituximab versus CHOP-like chemotherapy alone in young patients with good-prognosis diffuse large-B-cell lymphoma: a randomised controlled trial by the MabThera International Trial (MInT) Group. *The Lancet. Oncology* 2006; 7: 379-391.
42. Evens AM, Cilley J, Ortiz T et al. G-CSF is not necessary to maintain over 99% dose-intensity with ABVD in the treatment of Hodgkin lymphoma: low toxicity and excellent outcomes in a 10-year analysis. *Br J Haematol* 2007; 137: 545-552.
43. Fields PA, Townsend W, Webb A et al. De novo treatment of diffuse large B-cell lymphoma with rituximab, cyclophosphamide, vincristine, gemcitabine, and prednisolone in patients with cardiac comorbidity: a United Kingdom National Cancer Research Institute trial. *Journal of clinical oncology : official journal of the American Society of Clinical Oncology* 2014; 32: 282-287.
44. Lara PN, Jr., Natale R, Crowley J et al. Phase III trial of irinotecan/cisplatin compared with etoposide/cisplatin in extensive-stage small-cell lung cancer: clinical and pharmacogenomic results from SWOG S0124. *Journal of clinical oncology : official journal of the American Society of Clinical Oncology* 2009; 27: 2530-2535.



45. Hanna N, Bunn PA, Jr., Langer C et al. Randomized phase III trial comparing irinotecan/cisplatin with etoposide/cisplatin in patients with previously untreated extensive-stage disease small-cell lung cancer. *Journal of clinical oncology : official journal of the American Society of Clinical Oncology* 2006; 24: 2038-2043.
46. Wozniak AJ, Crowley JJ, Balcerzak SP et al. Randomized trial comparing cisplatin with cisplatin plus vinorelbine in the treatment of advanced non-small-cell lung cancer: a Southwest Oncology Group study. *Journal of clinical oncology : official journal of the American Society of Clinical Oncology* 1998; 16: 2459-2465.
47. Schiller JH, Harrington D, Belani CP et al. Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. *The New England journal of medicine* 2002; 346: 92-98.
48. du Bois A, Luck HJ, Meier W et al. A randomized clinical trial of cisplatin/paclitaxel versus carboplatin/paclitaxel as first-line treatment of ovarian cancer. *Journal of the National Cancer Institute* 2003; 95: 1320-1329.
49. Park DC, Kim JH, Lew YO et al. Phase II trial of neoadjuvant paclitaxel and cisplatin in uterine cervical cancer. *Gynecologic oncology* 2004; 92: 59-63.
50. Pectasides D, Xiros N, Papaxoinis G et al. Carboplatin and paclitaxel in advanced or metastatic endometrial cancer. *Gynecologic oncology* 2008; 109: 250-254.
51. Rose PG, Bundy BN, Watkins EB et al. Concurrent cisplatin-based radiotherapy and chemotherapy for locally advanced cervical cancer. *The New England journal of medicine* 1999; 340: 1144-1153.
52. Kundu S, Basu S, Acharya S et al. Chemoradiation in locally advanced cervical cancer: A randomized trial. *Indian Journal of Medical and Paediatric Oncology* 2008; 29: 12.
53. Heinemann V, Wilke H, Mergenthaler HG et al. Gemcitabine and cisplatin in the treatment of advanced or metastatic pancreatic cancer. *Annals of Oncology* 2000; 11: 1399-1403.
54. Greenberg HS, Chamberlain MC, Glantz MJ, Wang S. Adult medulloblastoma: multiagent chemotherapy. *Neuro-oncology* 2001; 3: 29-34.
55. Matzinger O, Roelofsen F, Mineur L et al. Mitomycin C with continuous fluorouracil or with cisplatin in combination with radiotherapy for locally advanced anal cancer (European Organisation for Research and Treatment of Cancer phase II study 22011-40014). *European journal of cancer (Oxford, England : 1990)* 2009; 45: 2782-2791.
56. Cummings BJ, Keane TJ, O'Sullivan B et al. Epidermoid anal cancer: treatment by radiation alone or by radiation and 5-fluorouracil with and without mitomycin C. *International journal of radiation oncology, biology, physics* 1991; 21: 1115-1125.
57. Flaherty KT, Lee SJ, Zhao F et al. Phase III trial of carboplatin and paclitaxel with or without sorafenib in metastatic melanoma. *Journal of clinical oncology : official journal of the American Society of Clinical Oncology* 2013; 31: 373-379.

58. Briasoulis E, Kalofonos H, Bafaloukos D et al. Carboplatin plus paclitaxel in unknown primary carcinoma: a phase II Hellenic Cooperative Oncology Group Study. *Journal of clinical oncology : official journal of the American Society of Clinical Oncology* 2000; 18: 3101-3107.